BRIDGETT FISK: Open Payments
NPI 1548889116 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,766 in 202 payments from 19 companies in 2025. Trend: 2023 $2,660 · 2024 $3,537 · 2025 $3,766
Food & beverage: $3,573Education: $193
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 30 | $730 |
| Teva Pharmaceuticals USA, Inc. | 28 | $660 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $427 |
| Otsuka America Pharmaceutical, Inc. | 24 | $307 |
| ABBVIE INC. | 21 | $288 |
| Axsome Therapeutics, Inc. | 14 | $246 |
| Lundbeck LLC | 10 | $216 |
| Vanda Pharmaceuticals Inc. | 11 | $175 |
| E.R. Squibb & Sons, L.L.C. | 14 | $164 |
| Janssen Pharmaceuticals, Inc | 5 | $153 |
Products named: INGREZZA, CAPLYTA, REXULTI, VRAYLAR, AUSTEDO XR, Auvelity, ABILIFY ASIMTUFII, UZEDY.
Industry payments across TX — which companies pay providers there.
